Mergers & acquisitions
With Kisqali going off patent and decreasing prices impacting sales, Novartis has narrowed sales guidance to 5% growth. But management remains steadfast that they have a plan to get back on track.
Merck is canning multiple Phase 3 studies of nemtabrutinib after a benefit-risk review derailed hopes of the asset entering the non-covalent BTK inhibitor race.
Acquiring a biotech with an existing Big Pharma partner can impose financial and strategic constraints around data sharing and milestone and royalty payments—but it is “rarely a deal-breaker,” according to one biotech consultant.
Blackstone will provide $750 million for Phase 3 development of Ollin Biosciences’ retinal disease bispecific as Johnson & Johnson looks to bolster its eye therapeutics pipeline after several setbacks.
Eli Lilly’s business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.
Unnatural Products has risen from founder Joshua Schwochert’s garage to an acquisition deal, valued at up to $1.15 billion, to join argenx.
After emraclidine’s schizophrenia fail and Cobenfy’s laggard launch, it’s too early to know who made the better buy: AbbVie, in its $8.7 billion Cerevel takeover in late 2023, or Bristol Myers Squibb, which spent $14 billion for Karuna just two weeks later.
AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not be the last for the hot ticket metabolic biotech.
Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with Ayrmid will go through.
“You don’t spend one and a half billion dollars without creating jobs,” AstraZeneca CEO Pascal Soriot said as the pharma announced a new cost savings program alongside third quarter earnings.
PRESS RELEASES